Cannabix Technologies Launches New Marijuana Breath Test Product Videos as U.S. Cannabis Reclassification Underscores the Urgent Need for Innovative Public Safety Solutions
Rhea-AI Summary
Cannabix Technologies (OTCID: BLOZF) launched new product videos on Dec. 19, 2025 showcasing its Marijuana Breath Test (MBT) and related hardware, including the Breath Collection Unit (BCU) and Breath Cartridge (BC).
The videos describe the MBT’s non-invasive breath sampling to detect recent cannabis use and show integration with gold-standard LC-MS analysis and a strategic partnership with Omega Laboratories for commercialization in the U.S. and Canada.
The company links the MBT to growing demand following the U.S. Administration’s reclassification action and positions the device for workplace and roadside screening applications.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BLOZF gained 8.73%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
VANCOUVER, British Columbia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has launched new product videos showcasing the Company’s Marijuana Breath Test (MBT) solution (Figures 1 and 2). These videos highlight the MBT’s advanced features and benefits, including its ability to detect recent cannabis use through non-invasive breath sampling—helping enhance workplace safety and providing law enforcement with innovative tools for roadside screening. The new videos can be viewed at www.cannabixtechnologies.com (see additional links below). The U.S. Administration’s executive order to fast-track the reclassification of marijuana to Schedule III under the Controlled Substances Act amplifies the spotlight on cannabis use and its growing liberalization across the country. This policy shift underscores the critical need for Cannabix’s Marijuana Breath Test (MBT) solution—providing an easy-to-use method to detect recent cannabis use and support public safety in workplaces and on highways.
Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies thumbnail from newly launched product video and corporate video.
The launch of this video marks a significant step in Cannabix’s marketing strategy, providing stakeholders with visuals and key features of how the MBT technology works and its role in addressing the growing need for THC breath detection.
Product Video Links:
https://cannabixtechnologies.com/
https://cannabixtechnologies.com/products/cannabix-marijuana-breath-test/
https://cannabixtechnologies.com/products/breathlogix-alcohol-breathalyzer/
The Marijuana Breath Test (MBT) system incorporates Cannabix’s proprietary Breath Collection Unit and Breath Cartridge technologies are designed to collect and preserve breath samples for analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a world-class facility with extensive experience in novel drug detection technologies. Together, Cannabix and Omega are advancing the commercialization of the MBT system for customers in the U.S. and Canada.
Figure 2. Cannabix Marijuana Breath Test hardware – Handheld Breath Collection Unit (BCU)
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to regulatory testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that patent applications are not awarded by regulatory authorities; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling the “MBT” and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/30915a38-8bd4-4feb-807d-3cb02e67a8c8
https://www.globenewswire.com/NewsRoom/AttachmentNg/08e32158-8ab4-4d4c-ba6c-68253b95c818
FAQ
What did Cannabix (BLOZF) announce on December 19, 2025 about the Marijuana Breath Test?
Where can investors watch the Cannabix (BLOZF) Marijuana Breath Test product videos?
How does the Cannabix (BLOZF) MBT collect and analyze breath samples?
What commercial partnership did Cannabix (BLOZF) highlight with the MBT launch?
How did the U.S. cannabis reclassification affect Cannabix (BLOZF) messaging about the MBT?
Will the Cannabix (BLOZF) videos explain how the MBT is used in workplace or roadside screening?
